| II-49 Yumi Cleary Physiologically –based pharmacokinetic (PBPK) and population PK (PPK) modeling for basimglurant - assessment of predicted variability by the PBPK model and its utility Wednesday 15:10-16:30 |
| II-49 Yumi Cleary Physiologically –based pharmacokinetic (PBPK) and population PK (PPK) modeling for basimglurant - assessment of predicted variability by the PBPK model and its utility Wednesday 15:10-16:30 |